TAD After Chemotherapy in Locally Advanced Breast Cancer

Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Feb 28, 2023

Keywords

ClinConnect Summary

This clinical trial, called "TAD After Chemotherapy in Locally Advanced Breast Cancer," is studying a surgical procedure known as target axillary dissection (TAD) in patients with locally advanced breast cancer. Specifically, it focuses on patients who have cancer that has spread to the lymph nodes under the arm and have undergone chemotherapy before surgery. The goal is to see if TAD can help improve outcomes for these patients.

To participate in this study, individuals must be between 65 and 74 years old and have certain characteristics, such as having at least four suspicious lymph nodes identified through ultrasound. However, patients with more advanced lymph node involvement or specific tumor types may not be eligible. Those who join the study can expect to undergo additional monitoring and analysis related to their treatment and recovery. This trial is currently recruiting participants and aims to gather important information to improve breast cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Axillary lymph node metastasis proven by cytology
• • Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
• • Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
• • Neoadjuvant chemotherapy
• Exclusion Criteria:
• • cN3 verified by imaging tests
• • N2 due to internal mammary involvement (N2b).
• • Tumors whose surrogate molecular subtype is luminal A.
• • Patients undergoing neoadjuvant endocrine therapy
• • Patients with local recurrences and metastatic tumors.